Uncategorized
Nemus, Nanomerics to develop ocular formulation for glaucoma treatment
Nemus Bioscience and Nanomerics have signed a development agreement to develop a topical ocular formulation of tetrahydracannabinol-valine-hemisuccinate, according to a Nemus press release.The active component of NB1111, a product candidate from Nemus for the treatment of glaucoma, is tetrahydracannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, the release said. The agreement involves initial studies assessing the preparation of clinical-grade eye drops using Nanomerics’ patented Molecular Envelope Technology (MET).